TCTMD - tctmd.com
WEBGiven the growing prevalence of heart failure worldwide, we recognize a clear mandate for developing new monitoring strategies and treatment options to increase survival, decrease hospitalizations, and improve quality of life — and for achieving these goals via a variety of potential interventions that target the various contributors to heart ...
TCT 2024 - TCTMD.com
WEBTCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of innovation in research and education that will help doctors save and improve the quality of their patients’ lives.
Injectable Semaglutide Shortage Forces Physicians to Pivot
WEBFeb 5, 2024 · And across the Atlantic, the European Medicines Agency has also put out a notice on a shortage of injectable semaglutide—specifically the Ozempic prefilled pens at doses of 0.25, 0.5, and 1 mg—due to both burgeoning demand and manufacturing issues. The agency said the shortfall is expected to continue through this year.
Study Supports Cost-effectiveness of Renal Denervation for …
WEBAug 23, 2024 · The overall cost-effectiveness of the procedure was relatively consistent across a variety of scenarios and sensitivity analyses. For example, ICERs ranged from $33,040 to $70,846 per QALY for patients ages 45 to 80 years, and from $31,884 to $41,524 per QALY for baseline office systolic BPs ranging from 140 to 175 mm Hg.
Blood Pressure Insights in COVID-19: Watch for Drops and RAAS …
WEBSep 10, 2020 · Here, Baher Al-Abbasi, MD (University of Miami/JFK Medical Center, Atlantis, FL), and colleagues noted increased in-hospital mortality in 172 COVID-19 patients taking ACE inhibitors or ARBs compared with those not taking the drugs (33% vs 13%; P = 0.003), as well as increased likelihood of admission to the …
Slides | tctmd.com
WEBApr 8, 2024 · Interventional Complications 2023. Seattle, WA. July 14. July 15, 2023. See All Conferences. The best online resource for cardiology conference slides around the globe.
Evoque and Patisiran: A Tale of Two Regulatory Journeys
WEBMar 29, 2024 · Evoque’s approval was supported by preliminary data from the pivotal trial TRISCEND II— results for the first 150 out of 392 patients were presented at TCT 2023. In the early phase data reported during the meeting, the trial met its primary safety endpoint—a composite of major adverse events at 30 days using a …
‘Provocative’ Projections See Semaglutide Slashing CV Events in …
WEBJun 27, 2024 · Mean BMI was 32.6 kg/m2, and 58% had a history of CAD, 51% MI, 48% stroke, and 23% PAD. Using the SMART2 risk calculator, the investigators estimated that 41% of these individuals would have at least one MACE over the next 10 years, with a total of more than 3 million projected events. That included about 1.3 million MIs, 674,000 strokes, and 1 ...
No Go for No-Touch SVG Harvesting in CABG Surgery: SWEDEGRAFT
WEBAug 31, 2024 · By Michael O'Riordan. August 31, 2024. LONDON, England—The “no-touch” harvesting technique for patients undergoing CABG surgery using a saphenous vein graft does not lower the risk of graft failure but is associated with a significantly increased risk of wound complications. Those are the conclusions of SWEDEGRAFT, a …
‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry
WEBJan 10, 2020 · With a list price of $225,000 per year, tafamidis is the most expensive cardiovascular drug on the market. Mathew Maurer, MD (Columbia University Irving Medical Center, New York, NY), who published his views along with Jerry Gurwitz, MD (University of Massachusetts Medical School, Worcester), January …